KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. - Wikidata - thesis-toulmin - TriplyDB

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.

http://www.wikidata.org/entity/Q37067360

about

Surgical pathology of early stage non-small cell lung carcinoma Clinical impacts of a micropapillary pattern in lung adenocarcinoma: a review Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail?Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients Association between histopathological subtype, (18)F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma.Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.Classification of different patterns of pulmonary adenocarcinomas.KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases.Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.Transition between morule-like and solid components may occur in solid-predominant adenocarcinoma of the lung: report of 2 cases with EGFR and KRAS mutations Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma.Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations

P2860

Q26739713-EA1700E1-6F48-474D-9453-24C4E4D32D6B Q26771950-B946CAD9-4FCE-436E-922A-41ABDEC28FCC Q27345462-B4789C0C-B2D4-499C-944B-E2DA4C95DF43 Q34141249-520ECDD9-1BC2-4F76-8C93-860C70622DEA Q34404229-D842441A-4298-4B90-B419-25E54C5C3F69 Q34748124-1DD3628E-73F6-4F9E-8C2F-DE8E47FCA164 Q35032336-1BD1A40A-EBCA-4079-A181-4500F6D4D248 Q35741716-159AB88C-B0F5-47CC-92FE-D726CE760DC2 Q35742165-5E332850-8BDE-4A41-899E-9C12CC894ECE Q36337437-DE24A790-F658-4CC7-860F-BF2579A21C99 Q36413817-40F1823F-4396-4D59-B2BA-01838ECF6B70 Q36474217-B087F4B7-79CC-4CF2-9643-60383722799E Q36477758-21C2E9BB-B2E7-4EAE-823B-FF4D4635EC94 Q36640546-461EBDD6-D644-44C7-AB5C-99881AB414D5 Q36741152-73FEB094-C4AD-45BB-9C66-4AAE8AC7CDD8 Q36924440-B227D7CE-7589-46D0-B5CF-64344F70A792 Q36952283-D503C1D0-E638-4CF5-B9DF-192C17CD5D11 Q37269159-3E3AE5B8-ABA3-4EEC-88F5-C0139E4758F8 Q38271717-3856FEB6-A92A-4960-95A3-B3E4C62B6080 Q38574971-9084A7DF-1541-441A-895D-7CC85A970EAC Q38669282-385D71E3-0A4C-4C14-AF59-FF72732D7A87 Q38797202-548C8491-AABF-4A9B-8724-BB8FBA952F8B Q39626850-7DDF2EF4-7B31-4DCA-8353-7528B74BFBA6 Q40070868-CBCA73A5-068C-4492-A8D8-4E41249FBCB8 Q40542208-0AADBA62-625F-49B5-AAAC-8A0E352A3BAD Q40559241-2D603429-60DC-4F02-8F21-D39D5DE66714 Q41904659-37C1DBC9-5837-41BB-B4A2-261FDCDE4658 Q48301301-67903E97-D766-4BBF-9EF8-80B1E4ED9954 Q51823617-390FB16F-9650-4C6E-A5F6-3059710ADE6F Q58407647-D4DC3C82-90DA-41D5-B61B-1D8EAE355BFD

P2860

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.

http://www.wikidata.org/entity/Q37067360

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@en

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@nl

type

label

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@en

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@nl

prefLabel

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@en

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@nl

P1433

Q37067360-7D72E892-79FC-4E62-BE51-A9D33D9A32C5

P1476

Q37067360-864865DA-DA86-4F24-BCFD-AED6ED04812A

P2093

Q37067360-08607E81-FF2C-4BAD-814A-66476D6AAC63

Q37067360-3A8A8E04-F9B7-4C80-ABE5-3166E1A34254

Q37067360-9C0C22EE-6764-4B31-96B9-5C01A74AC891

Q37067360-ABC7A1A3-27D0-42F9-A53E-A12D9C8C13D4

P2860

Q37067360-080227F7-F46A-4792-A713-47E4B1EE6DA1

Q37067360-13ECFE7C-E3D9-4568-80A7-09313B3743EF

Q37067360-198B3FD9-00DB-48F3-AD38-BC766D4D98ED

Q37067360-1B591262-26C9-48FA-87A9-DA34A3947B70

Q37067360-1DD40CC8-5D6E-40C5-ACB0-AB9ECCB2B7BA

Q37067360-1E5002A3-A870-4E3D-938E-56CC9FCE45CD

Q37067360-1FA9BD58-9D26-4512-BEA8-8BB89FB55076

Q37067360-20763566-F5A6-4956-9EB6-DFA781BF4BFA

Q37067360-271CB046-BC58-40CD-943C-9C6FB2D674B5

Q37067360-2C5BCEC1-A484-4464-85DA-7B44DF8BAA95

P2888

Q37067360-83D880C7-00D7-42AE-96E9-9585496E5B76

P304

Q37067360-00F15B12-4C9D-4CE0-99A0-D1590ADA08CB

P31

Q37067360-F1235F00-E988-4631-9108-97252A12CBC2

P356

Q37067360-D733D698-2BA2-4C7E-8583-BBC2C2306B27

P433

Q37067360-ABFE4AB4-A198-4DF6-B465-C3A6BF746039

P478

Q37067360-EC849088-BCCE-4B51-80C2-E14DC3344B79

P50

Q37067360-AE1E0090-59E9-4DAF-9E7A-FAD284C1AE34

P577

Q37067360-300D72E1-9760-4FDB-9A70-EEB9097FBBA8

P5875

Q37067360-D521B335-C09F-4E7E-B00F-2064D692E13C

P698

Q37067360-DD220BF4-59F4-4137-B54F-B91C0574FFEC

P921

Q37067360-96FD8F79-6D39-4723-BFEA-D21B265B2650

P932

Q37067360-24ED4404-8FD7-42FA-A26F-E26F10F12E9D

P356

MODPATHOL.2013.74

P1433

Modern Pathology

P1476

KRAS mutations are associated ...... ocytes in lung adenocarcinoma.

@en

P2093

Andre L Moreira

http://www.w3.org/2001/XMLSchema#string

Daphne C Ang

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Natasha Rekhtman

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

Molecular pathology of lung cancer: key to personalized medicine.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

KRAS mutations in non-small cell lung cancer

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

P2888

modpathol.2013.74

P304

1307-1319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2013.74

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236338732

http://www.w3.org/2001/XMLSchema#string

P698

23619604

http://www.w3.org/2001/XMLSchema#string

P921

P932

3732528

http://www.w3.org/2001/XMLSchema#string